228 related articles for article (PubMed ID: 18388150)
1. Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.
Berry NB; Fan M; Nephew KP
Mol Endocrinol; 2008 Jul; 22(7):1535-51. PubMed ID: 18388150
[TBL] [Abstract][Full Text] [Related]
2. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
Fan M; Park A; Nephew KP
Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.
Long X; Nephew KP
J Biol Chem; 2006 Apr; 281(14):9607-15. PubMed ID: 16459337
[TBL] [Abstract][Full Text] [Related]
4. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Fan M; Bigsby RM; Nephew KP
Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
[TBL] [Abstract][Full Text] [Related]
5. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
7. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor.
Tateishi Y; Kawabe Y; Chiba T; Murata S; Ichikawa K; Murayama A; Tanaka K; Baba T; Kato S; Yanagisawa J
EMBO J; 2004 Dec; 23(24):4813-23. PubMed ID: 15538384
[TBL] [Abstract][Full Text] [Related]
8. Ligands specify estrogen receptor alpha nuclear localization and degradation.
Kocanova S; Mazaheri M; Caze-Subra S; Bystricky K
BMC Cell Biol; 2010 Dec; 11():98. PubMed ID: 21143970
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation.
Tsai HW; Katzenellenbogen JA; Katzenellenbogen BS; Shupnik MA
Endocrinology; 2004 Jun; 145(6):2730-8. PubMed ID: 15033909
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
12. Clomiphene citrate down-regulates estrogen receptor-α through the ubiquitin-proteasome pathway in a human endometrial cancer cell line.
Amita M; Takahashi T; Igarashi H; Nagase S
Mol Cell Endocrinol; 2016 Jun; 428():142-7. PubMed ID: 27033325
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
[TBL] [Abstract][Full Text] [Related]
14. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.
Valley CC; Métivier R; Solodin NM; Fowler AM; Mashek MT; Hill L; Alarid ET
Mol Cell Biol; 2005 Jul; 25(13):5417-28. PubMed ID: 15964799
[TBL] [Abstract][Full Text] [Related]
16. Identification of an estrogen receptor α non covalent ubiquitin-binding surface: role in 17β-estradiol-induced transcriptional activity.
Pesiri V; La Rosa P; Stano P; Acconcia F
J Cell Sci; 2013 Jun; 126(Pt 12):2577-82. PubMed ID: 23591816
[TBL] [Abstract][Full Text] [Related]
17. Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7.
Peekhaus NT; Chang T; Hayes EC; Wilkinson HA; Mitra SW; Schaeffer JM; Rohrer SP
J Mol Endocrinol; 2004 Jun; 32(3):987-95. PubMed ID: 15171727
[TBL] [Abstract][Full Text] [Related]
18. The pure estrogen receptor antagonist ICI 182,780 promotes a novel interaction of estrogen receptor-alpha with the 3',5'-cyclic adenosine monophosphate response element-binding protein-binding protein/p300 coactivators.
Jaber BM; Gao T; Huang L; Karmakar S; Smith CL
Mol Endocrinol; 2006 Nov; 20(11):2695-710. PubMed ID: 16840538
[TBL] [Abstract][Full Text] [Related]
19. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src.
Liu H; Qiu J; Li N; Chen T; Cao X
J Biol Chem; 2010 Jul; 285(29):21934-42. PubMed ID: 20460377
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
